Biosimilar
An FDA Purple Book Compendium
About
This app serves as a reference for biosimilar and interchangeable biologic drugs, drawing from the FDA's Purple Book. It offers essential prescribing and dispensing information for healthcare professionals managing complex drug therapeutics.
What's New in Biosimilar
1.0.6
May 20, 2026
* cleaned up UI for iOS 26 * fixed a bug preventing proper database updates
Charts
Developer apps
FAQ
What is Biosimilar?
Biosimilar is an iOS app that provides a reference to the FDA's Purple Book, containing information on biosimilar and interchangeable biologic drugs. It is designed for clinicians and pharmacists.
Is Biosimilar free?
No, Biosimilar is a paid application. It is available for purchase at $1.99 on the App Store. The app does not feature advertisements or in-app purchases.
What devices does Biosimilar support?
Biosimilar is compatible with iPhone and iPad devices. It is designed to run on Apple's iOS operating system.
How often is Biosimilar updated?
The latest version of Biosimilar is 1.0.6, last updated on May 20, 2026. The app was initially released on January 15, 2023.
What is the age rating for Biosimilar?
Biosimilar has an age rating of 17+. This rating is typically assigned to apps that may contain mature content or themes not suitable for younger audiences.
What is the user sentiment for Biosimilar?
Biosimilar has received a perfect rating of 5.0 stars from 2 user reviews. This indicates a highly positive user sentiment among its current users.
Does Biosimilar have ads?
No, Biosimilar does not contain advertisements. As a paid application, it offers an ad-free experience for its users.
Should non-medical users use Biosimilar?
The app's disclaimer advises non-medical users to seek a doctor's advice in addition to using the app and before making any medical decisions. It is primarily intended for healthcare professionals.
